| LXR-alpha Protein | |
|---|---|
| Protein Name | LXR-alpha Protein |
| Gene Symbol | NR1H3 |
| UniProt ID | Q9GZN5 |
| PDB Structures | 3IPQ, 3IPS, 4NLL |
| Molecular Weight | 50 kDa |
| Subcellular Localization | Nucleus |
| Protein Family | Nuclear Receptor Family |
LXR-alpha is a protein involved in cellular signaling and transcriptional regulation.[1] This protein plays important roles in regulating gene expression and cellular signaling.[2] In the context of neurodegenerative diseases, LXR-alpha is implicated in Alzheimer's disease, Parkinson's disease, and other disorders through various mechanisms.[3]
NR1H3 (LXR-alpha) has a typical nuclear receptor structure with an N-terminal AF-1 domain, a DNA-binding domain (DBD) with two zinc fingers, a hinge region, and a ligand-binding domain (LBD). The LBD contains a hydrophobic pocket that binds oxysterols as natural ligands. NR1H3 forms heterodimers with RXRA and binds to LXR response elements (LXREs). The protein has ligand-dependent transcriptional activation function.
NR1H3 (LXR-alpha) is a nuclear receptor that regulates genes involved in cholesterol metabolism, lipid transport, and inflammation. It binds oxysterols as natural ligands and activates genes involved in reverse cholesterol transport including ABCA1 and ABCG1. LXR-alpha also regulates fatty acid synthesis, glucose metabolism, and has anti-inflammatory effects. It plays important roles in lipid homeostasis in various tissues.
NR1H3/LXR-alpha is implicated in neurodegenerative diseases through cholesterol metabolism and inflammation. In Alzheimer's disease, LXR activation promotes amyloid-beta clearance through upregulation of cholesterol efflux genes. LXR agonists show protective effects in AD models. In Parkinson's disease, LXR activation protects dopaminergic neurons. LXR also has anti-inflammatory effects in glial cells. Brain-penetrant LXR agonists are being developed for neurodegeneration.
LXR agonists (GW3965, T0901317) have shown protective effects in neurodegenerative disease models. However, first-generation LXR agonists caused side effects including hypertriglyceridemia and liver steatosis. Newer LXR modulators with improved brain penetration and reduced side effects are under development. LXR-beta (NR1H2) selective agonists may avoid some side effects. Gene therapy approaches are also being explored.